Following early work in model system genetics, Exelixis established a broad drug discovery and development platform that has served as the foundation for the company’s continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer.
Please see our community guidelines: bit.ly/2XXw9w3.
To learn about us, visit www.exelixis.com/mission.
Location: United States, California, Alameda
Employees: 501-1000
Phone: +1 650-837-7000
Founded date: 1994
Investors 3
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| 22.09.2022 | Internatio... | ibtplc.com |
| - | Atlas Vent... | atlasventu... |
Mentions in press and media 16
| Date | Title | Description | Source |
| 13.09.2023 | Exelixis and Insilico Medicine Enter into Exclusive Global L... | — ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1 identified th... | en.prnasia... |
| 02.11.2022 | Exelixis shells out $100M cash in a pair of deals, shooti... | Now that its cabozantinib franchise — including Cabometyx tablets and Cometriq capsules — has... | endpts.com... |
| 14.10.2021 | Exelixis and STORM enter into exclusive collaboration to dis... | Exelixis and STORM Therapeutics enter into exclusive collaboration and license agreement to discover... | cic.vc/new... |
| 30.06.2021 | Will Exelixis Stock See Even Lower Levels After Negative Dat... | BRAZIL - 2020/11/04: In this photo illustration the Exelixis logo seen displayed on a smartphone. ..... | forbes.com... |
| 04.05.2021 | Life Sciences portfolio company Gamamabs signs an agreement ... | To read the detailed press release, please click here | anderapart... |
| 18.03.2021 | Exelixis Announces Clinical Trial Collaboration and Supply A... | ALAMEDA, Calif.--(BUSINESS WIRE)--Mar 18, 2021-- Exelixis, Inc. (Nasdaq:EXEL) today announced a cli... | oaoa.com/n... |
| 25.02.2021 | Exelixis Announces Breakthrough Therapy Designation Granted ... | ALAMEDA, Calif.--(BUSINESS WIRE)--Feb 25, 2021-- Exelixis, Inc. (NASDAQ: EXEL) today announced that... | oaoa.com/n... |
| 08.09.2020 | News briefing: Exelixis rolls the dice with 2 ADC deals t... | Peter Lamb Catalent’s Redwood Bioscience subsidiary is taking the lead role in developing ... | endpts.com... |
| 04.09.2016 | The biotech empires of Silicon Valley and Europe | Bérénice Magistretti Contributor Bérénice Magistretti is a Swiss freelance writer based in San Fran... | techcrunch... |
| 17.04.2015 | Stealth San Diego startup Metacrine raising $33M. Are we rea... | Evans, Metacrine’s founder, is a lauded gene expression researcher at the Salk Institute who has a n... | medcitynew... |
Show more